EMA Authorised: Cinryze (C1 inhibitor (human)) — Takeda Manufacturing Austria AG

View source ↗

Summary

The European Medicines Agency authorised Cinryze for hereditary angioedema, with Takeda Manufacturing Austria AG as the marketing authorization holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• Cinryze (C1 esterase inhibitor)

Snippet

Status: Authorised. Therapeutic area: Angioedemas, Hereditary. MAH: Takeda Manufacturing Austria AG. Decision date: 08/05/2025